On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...

In its new incarnation, apecotrep has been shown to reduce protein in the urine (proteinuria) – a biomarker for kidney ...

The Surf Bio acquisition comes shortly after Halozyme bought another company with a subcutaneous delivery technology, ...

Traditional cell therapies rely on “clean targets” – antigens that are found on cancer cells but not on healthy cells. Where ...

By prioritising gentler, patient-focused approaches, the field of paediatric MRI has seen significant advances, while its use ...

That is the conclusion of the annual assessment of the sector's ability to attract financing by the BioIndustry Association ...

The list has been announced by the Centers for Medicare & Medicaid Services (CMS) shortly after the reductions agreed for the ...

The South San Francisco startup is offering 17.6 million shares at a price range of $16 to $18, which would give the company a valuation at the top end of more than $900 million. The IPO follows ...

Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...

The phase 2 trial of CT-388, a once-weekly subcutaneous injection acquired as part of its $2.7 billion takeover of Carmot ...

Huahui Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus (HDV), ...

In this second of three articles on The Sunday Times top 100 tech companies list, pharmaphorum is focusing on the first nine ...